✦ LIBER ✦

21 The survival benefit of erlotinib in the management of advanced non-small cell lung cancer (NSCLC) in the routine clinical practice; a retrospective study

✍ Scribed by Daverede, L.; Elmahdawi, N.; Scott, C.; Bozas, G.; Upadhyay, S.; Dhadda, A.; Butt, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel (Taxotere®) in the management

✍ Miller, Vincent A. 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 133 KB

Clinical retrospective analysis of erlot

✍ Marco Platania; Francesco Agustoni; Barbara Formisano; Milena Vitali; Monika Duc 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 101 KB

PCN12 COST EFFECTIVENESS OF ERLOTINIB IN

✍ E Orlewska; A Szczesna; M Gyldmark; M Szkultecka-Debek 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

Efficacy of erlotinib in patients with a

✍ Michael BOYER; Keith HORWOOD; Nick PAVLAKIS; Paul DE SOUZA; Michael MILLWARD; Br 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

Combined radio-chemotherapy in the manag

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 183 KB

The limited clinical benefit of respirat

✍ Muirhead, R.; Featherstone, C.; Duffton, A.; Moore, K.; McNee, S. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 56 KB